Ignite Creation Date:
2024-07-17 @ 11:04 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06479135
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-21
Brief Title:
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Sponsor:
Organization:
Kartos Therapeutics Inc